[{"orgOrder":0,"company":"Tigermed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Tigermed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Inapplicable"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TNM002","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Frontage Laboratories, Inc \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Frontage Laboratories, Inc \/ Eisai"},{"orgOrder":0,"company":"Tigermed","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Multitude Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AMT-151","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TL-001","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Zhejiang Hisun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VG290131","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Mira Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc"},{"orgOrder":0,"company":"Tigermed","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"11","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Immorna","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"JCXH-105","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"8","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Shanghai Zhimeng Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ZM-H1505R","moa":"Hepatitis B virus Capsid protein (HBV C)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"8","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"HighField Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HF1K16","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Immorna","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"JCXH-108","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Silo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"SPC-15","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc","highestDevelopmentStatusID":"5","companyTruncated":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Sonidor","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Pediafl\u00f9","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Diosmin","moa":"Aryl hydrocarbon receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Tigermed \/ Tigermed"}]
Find Clinical Drug Pipeline Developments & Deals by Tigermed
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
